Computer systems used in the testing of a drug product are not of appropriate design to facilitate operations for its intended use.
Inspection Record
Biocon Biologics Limited — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that components and in-process materials conform to appropriate standards of identity, strength, quality and purity.
Your firm's facilities are not adequate to ensure the prevention ofcontamination ofequipment or product by environmental conditions that could reasonably be expected to have an adverse effect on product quality.
Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established and followed.
Written records of investigations into unexplained discrepancies and the failure ofa batch or any of its components to meet specifications do not always include the conclusions and follow-up.
There is a lack of assurance that your cleaning procedures for the shared product-contact process equipment in your Drug Substance and Fill-Finish product manufacturing facilities, are effective in preventing cross-contamination.
GMP Equipment is used outside its validated aceeptance criteria for critically controlled matenal, Specifically, Quality Control Stability Chambers, QC-Q13-Al-141 and QC-Q13-AI-142, located in QC Building (13, are validated for 2— 8 °C and both have had numerous excursions from their validated temperature over the past two year, Additionally, these excursions have not triggered deviations to be opened.
Deviations from written test procedures and laboratory mechanisms are not recorded and justified.
Your firm has not established adequate procedural controls to protect the ic data acquisition and/or manufacturing control systems used for DS and DP manufacturing in your Site manufacturing facilities, Specifically, A.
aot CRD IS Fo) Gel | ewrucrese en ORMAE: ALM TFTLIE: (PSA oe Th OTe Beep SEE Michael F.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Fenwal International, Inc.2024-09-18 · US FDASimilar to finding 2 Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that in-process materials…
- Dendreon Pharmaceuticals LLC2026-03-25 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
- Eugia Pharma Specialities Limited2025-11-14 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
- ROSLIN CELL THERAPIES LIMITED2025-01-21 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
- Sanofi Pasteur2023-09-29 · US FDASimilar to finding 4 Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not followed.
A record as of the US FDA document published on 2022-09-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.